Online inquiry

IVTScrip™ mRNA-Human Carboxypeptidase M, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WK3430MR)

This product GTTS-WK3430MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the Carboxypeptidase M protein. This product can be used in -related researches.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Human
RefSeq NM_001005502.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1368
UniProt ID P14384
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Human Carboxypeptidase M, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WK3430MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WK10607MR IVTScrip™ mRNA-Human ACADM, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ACADM
GTTS-WK20266MR IVTScrip™ mRNA-Human AMZ2P1, (Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMZ2P1
GTTS-WK23328MR IVTScrip™ mRNA-Human ASS1, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ASS1
GTTS-WK8552MR IVTScrip™ mRNA-Human ACSM2B, (Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ACSM2B
GTTS-WK2101MR IVTScrip™ mRNA-Human Intestinal Alkaline Phosphatase, (Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Intestinal Alkaline Phosphatase
GTTS-WK28798MR IVTScrip™ mRNA-Human ATP5E, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ATP5E
GTTS-WK14162MR IVTScrip™ mRNA-Human ABHD13, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABHD13
GTTS-WK9745MR IVTScrip™ mRNA-Human ACSF3, (Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ACSF3
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW